Evaluation of the Safety, Genetic Stability, and Immunogenicity of an Attenuated Shigella Live Vector Expressing Enterotoxigenic Escherichia coli Antigens, Vaccine Strain CVD 1208S-122
The Journal of Infectious Diseases · 2026
DOI: 10.1093/infdis/jiag220 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift The Journal of Infectious Diseases, 2026. Verfasst von Wilbur H Chen und 13 weiteren Autor:innen. Beteiligte Einrichtung: Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA. Hauptthemen laut MEDLINE: Antigens, Bacterial, Enterotoxigenic Escherichia coli, Escherichia coli Infections, Escherichia coli Vaccines. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, NCI NIH HHS, NCATS NIH HHS.
Abstract (Originalsprache)
Background
There are no licensed vaccines to protect against Shigella or enterotoxigenic Escherichia coli (ETEC), yet they are among the most common causes of bacterial diarrhea. We engineered an attenuated Shigella flexneri 2a expressing colonization factor antigen 1 (CFA/I) and heat-labile enterotoxin B subunit (LTB) from ETEC and conducted a first-in-human randomized-controlled trial of ascending doses of the vaccine (CVD 1208S-122).
Methods
Dose-escalating cohorts received a single oral dose of 108–1010 colony-forming units (CFU) of CVD 1208S-122 or placebo. A fourth cohort received 1 or 2 oral doses of 108 CFU CVD 1208S-122 or placebo. We measured the safety and clinical acceptability of the vaccine, genetic stability of fecally shed vaccine organisms, and immune responses elicited.
Results
The 108 CFU doses were well tolerated (100%, 6/6). One recipient of 109 CFU (20%, 1/5) manifested diarrhea and 4 individuals who ingested 1010 CFU had either fever or diarrheal reactogenicity (67%, 4/6). Fecal shed vaccine organisms were genetically stable. Responses were observed to the lipopolysaccharide (LPS) and invasion plasmid antigen B (IpaB) of Shigella and CFA/I fimbriae and LTB of ETEC in serum, among antibody secreting cells, antibody in lymphocyte supernatant, and fecal samples. Serum antibodies exhibited Shigella bactericidal activity and inhibition of ETEC adherence in vitro.
Conclusions
This study demonstrates safety with low-dose but unacceptable reactogenicity following highest-dose ingestion, genetic stability of all recovered fecal isolates, and immunogenicity of a prototype combined monovalent Shigella-ETEC vaccine. These results encourage expansion to a multivalent formulation to elicit broader protection against the most prevalent Shigella serotypes and ETEC CFA types that cause diarrheal disease. Clinical Trials Registration NCT04634513.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA.
- Program in Oncology, University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore, Maryland, USA.
- Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
- Division of Biostatistics and Bioinformatics, Department of Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore, Maryland, USA.
ORCID-Profile: Wilbur H Chen, Eileen M Barry, Franklin R Toapanta, Marcela F Pasetti, Marcelo B Sztein, Jasnehta Permala-Booth, Sharon M Tennant, Justin R Ortiz, Megan McGilvray, Lynnee Roane, Reva Datar, Myron M Levine
Förderung
- NIAID NIH HHS
- NCI NIH HHS
- NCATS NIH HHS
- National Institute of Allergy and Infectious Diseases
- Institute for Clinical and Translational Research
- University of Maryland, Baltimore
- General Clinical Research Center, University of Maryland
- NIH
Zitieren
APA
Chen, W. H., Barry, E. M., Toapanta, F. R., Pasetti, M. F., Sztein, M. B., Permala-Booth, J., Tennant, S. M., Ortiz, J. R., Thomas, C., McGilvray, M., Roane, L., Datar, R., Liang, Y., & Levine, M. M. (2026). Evaluation of the Safety, Genetic Stability, and Immunogenicity of an Attenuated Shigella Live Vector Expressing Enterotoxigenic Escherichia coli Antigens, Vaccine Strain CVD 1208S-122. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiag220
Vancouver
Chen WH, Barry EM, Toapanta FR, Pasetti MF, Sztein MB, Permala-Booth J, et al. Evaluation of the Safety, Genetic Stability, and Immunogenicity of an Attenuated Shigella Live Vector Expressing Enterotoxigenic Escherichia coli Antigens, Vaccine Strain CVD 1208S-122. The Journal of Infectious Diseases. 2026. doi:10.1093/infdis/jiag220
BibTeX
@article{Chen2026,
author = {Chen, Wilbur H and Barry, Eileen M and Toapanta, Franklin R and Pasetti, Marcela F and Sztein, Marcelo B and Permala-Booth, Jasnehta and Tennant, Sharon M and Ortiz, Justin R and Thomas, Constance and McGilvray, Megan and Roane, Lynnee and Datar, Reva and Liang, Yuanyuan and Levine, Myron M},
title = {Evaluation of the Safety, Genetic Stability, and Immunogenicity of an Attenuated Shigella Live Vector Expressing Enterotoxigenic Escherichia coli Antigens, Vaccine Strain CVD 1208S-122},
journal = {The Journal of Infectious Diseases},
year = {2026},
doi = {10.1093/infdis/jiag220}
}
EUVIMED